This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, epidemiology information, licensing and asset acquisition deals, and drug-specific revenues.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 09 September 2021
Number of pages:29
This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, upcoming events, clinical trials, probability of success, and epidemiology information.
Approved drugs in the ADHF – preserved ejection fraction (acute HFpEF) space target natriuretic peptide receptors. These drugs are administered via the intravenous route.
Approved drugs in the ADHF – reduced ejection fraction (acute HFrEF) space target natriuretic peptide receptors, phosphodiesterase 3, potassium channels, and troponin-C. All of the approved therapies are administered via the intravenous route, with two drugs also being available in an oral formulation.
The industry-sponsored drugs in active clinical development for acute HFrEF are equally distributed between Phase I and Phase II.
Therapies in development for acute HFrEF target guanylate cyclase, ryanodine receptor, sarcoplasmic reticulum Ca2+-ATPase, troponin, beta-3 adrenergic receptor, relaxin family peptide receptors 1–4, and natriuretic peptide receptors. These therapies are administered via the intravenous and oral routes.
High-impact upcoming events for drugs in the acute HFrEF space comprise topline Phase II trial results for istaroxime, topline Phase IIa trial results for APD418, and topline Phase IIb trial results for cimlanod.
The overall likelihood of approval of a Phase I acute HFrEF asset is 1.5%, and the average probability a drug advances from Phase III is 28.6%. Drugs, on average, take 13.5 years from Phase I to approval, compared to 10.2 years in the overall cardiovascular space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for ADHF have been in the late phases of development, with 58% of trials in Phase III–IV, and 42% in Phase I–II.
Clinical trial activity in the ADHF space is dominated by completed trials. Johnson & Johnson has the highest number of completed clinical trials for ADHF, with 17 trials.
Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for ADHF, followed by Novartis.
23 CLINICAL TRIAL LANDSCAPE
24 Sponsors by status
25 Sponsors by phase
LIST OF FIGURES
17 Figure 1: Overview of pipeline drugs for acute HFrEF in the US
17 Figure 2: Pipeline drugs for acute HFrEF by, company
18 Figure 3: Pipeline drugs for acute HFrEF by, drug type
18 Figure 4: Pipeline drugs for acute HFrEF by, classification
21 Figure 5: Key upcoming events in acute HFrEF
22 Figure 6: Probability of success in the ADHF pipeline
23 Figure 7: Clinical trials in ADHF
23 Figure 8: Top 10 drugs for clinical trials in ADHF
24 Figure 9: Top 10 companies for clinical trials in ADHF
25 Figure 10: ADHF trials status
26 Figure 11: ADHF trials sponsors, by phase
LIST OF TABLES
14 Table 1: Marketed drugs for acute HFpEF
16 Table 2: Marketed drugs for acute HFrEF
19 Table 3: Pipeline drugs for acute HFrEF in the US
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726